Clozapine N-oxide
Clozapine N-oxide structure
|
Common Name | Clozapine N-oxide | ||
|---|---|---|---|---|
| CAS Number | 34233-69-7 | Molecular Weight | 342.823 | |
| Density | 1.36g/cm3 | Boiling Point | 517.4ºC at 760mmHg | |
| Molecular Formula | C18H19ClN4O | Melting Point | 190-248ºC | |
| MSDS | Chinese USA | Flash Point | 266.7ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of Clozapine N-oxideClozapine N-oxide (CNO) is a major metabolite of the anti-psychotic drug clozapine. Clozapine N-oxide is a agonist for the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD) system. |
| Name | clozapine n-oxide |
|---|---|
| Synonym | More Synonyms |
| Description | Clozapine N-oxide (CNO) is a major metabolite of the anti-psychotic drug clozapine. Clozapine N-oxide is a agonist for the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD) system. |
|---|---|
| Related Catalog | |
| Target |
DREADD[1] |
| In Vivo | After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Acutely administered CNO can be metabolically converted to Clozapine in other species such as human and guinea-pig. The metabolites that may form after chronic administration of CNO to DREADD-expressing mice (or other species) have not been studied systematically. However, even if back-transformation to Clozapine occurs after chronic CNO administration, it should be noted that Clozapine is a more potent (by ~10-fold) DREADD agonist than CNO itself. Moreover, confounding biological effects of potential CNO metabolites can be easily identified by including both saline- and CNO-treated WT animals in a particular DREADD study. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h). One possibility is that CNO tends to accumulate in tissues, although other scenarios are also feasible[1]. Using a general pharmacokinetic model for the interconversion process, the mean total clearances of Clozapine and Clozapine N-oxide (CNO) are 28.45 L/hr and 45.30 L/hr, respectively[2]. |
| References |
| Density | 1.36g/cm3 |
|---|---|
| Boiling Point | 517.4ºC at 760mmHg |
| Melting Point | 190-248ºC |
| Molecular Formula | C18H19ClN4O |
| Molecular Weight | 342.823 |
| Flash Point | 266.7ºC |
| Exact Mass | 342.124725 |
| PSA | 57.06000 |
| LogP | 0.76 |
| Index of Refraction | 1.685 |
| Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H315-H319-H335 |
| Precautionary Statements | P261-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | UN 2811 6.1/PG 3 |
| RTECS | HP1760000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
|
Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks.
J. Clin. Invest. 123(12) , 5342-50, (2013) The ability to map the functional connectivity of discrete cell types in the intact mammalian brain during behavior is crucial for advancing our understanding of brain function in normal and disease s... |
|
|
Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression.
J. Clin. Invest. 123(12) , 5334-41, (2013) Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala... |
|
|
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
J. Med. Chem. 52 , 4266-76, (2009) The cardiac hERG K(+) channel constitutes a long-standing and expensive antitarget for the drug industry. From a study of the flexibility of hERG around its internal binding cavity, we have developed ... |
| 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide |
| 8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine |
| 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-4-oxido-1-piperazinyl)- |
| Clozapine N-oxide |
| Clozapine (N-oxide) |